rHuEpo is pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the protein’s structure resulted in novel Epo like agents. Epo mimetic agents and agents to increase endogenous production are underway. As Epo has tissue protective actions outside of erythropoiesis, designs try producing erythro-inactive molecules that still retain extra-hematopoietic activity. Data that Epo can trigger signaling in some cancer cells has raised attention of medical community and regulatory authorities.
COBISS.SI-ID: 24260313
rHuEPO is used in medicine, it acts as a stimulus for production of red cells. Detection method that could differentiate between endogenous and exogenous EPO was developed in 2000, when the method called isoelectric focusing (IEF) was first used for detection of doping in sport. The problem of rHuEPO detection is structural similarity to endogenous EPO and low concentration of EPO in human blood and urine. IEF is currently not used as diagnostic method in clinical samples. It has potency to be used as method to identify the effects of rHuEpo and other therapy on endogenous EPO expression.
COBISS.SI-ID: 111111111